HEMAX
BIOSIDUS
Identification
- Active ingredient (INN)
- EPOETINE ALPHA
- Internal code
- 12 E 123
- Country of Origin
- Algeria
- Pharmaceutical form
- Lyophilised Powder + Solvent for IV/SC Injectable Sol.
- Prescription List
- Highly Regulated (List I)
- Packaging
- b/ 01 flacon de poudre lyoph+01ampoule de 2ml de solv +01 seringue+02aiguilles a usage unique ou b/ 25 flacon de poudre lyoph+25ampoule de 2ml de solv
DAWA Clinical Workbench v2.0
Information may not be accurate. Always consult a physician, pharmacist, or specialist before acting on any data shown here.
Associated Conditions
Lactation Anemia in cancer patients Iron deficiency anaemia History of thromboembolic accident History of seizures Carence in folic acid and vitamin B12 Epilepsy Inflammatory Pregnancy Haemolysis Haemorrhage Hepatitis C Central nervous system infection Chronic hepatic impairment Chronic renal impairment Interchangeability Orthopaedic surgery Aluminium poisoning Brain metastasis Myelofibrose Infant under 1 year of age Obesity Patient subject to autologous sampling Porphyry Sports Subject at risk of thromboembolic accident Subject at risk of seizure.
Mechanism of Action
Epoetin zeta
Mechanism of action Erythropoietin is a glycoprotein that stimulates, as mitosis and differentiation hormone stimulation factors, the formation of erythrocytes of cell compartment precursors.
The apparent molecular weight of erythropoietin is 32 000-40 000 daltons.
The protein section of the molecule represents approximately 58% of the total molecular weight and consists of 165 amino acids.
The four carbohydrate chains are fixed via three N-glycosidic bonds and an O-glycosidic bond to the protein.
Epoetin zeta is identical in terms of amino acid sequence and similar in terms of glucidic composition to endogenous human erythropoietin isolated in the urine of anemic patients.
The biological efficacy of erythropoietin has been demonstrated in several animal models in vivo (normal and anaemic rats, polycythememic mice).
Following administration of erythropoietin, the number of erythrocytes, the levels of recythrocytes, the levels of Hb, and the levels of recyticuloses increase.
Adverse Effects
- Hyperkalaemia (Uncommon)
- Antibody antierythropoetin (Rare)
- Urticaria (Uncommon)
- Stevens-Johnson Syndrome
- Rash Severe skin reaction Lyell's syndrome Frisher (Common)
- Fever (Very common)
- Peripheral edema (Common)
- Pain in the extremities (Common)
- Irflu pseudo-influenza syndrome Treatment failure
- Thrombocytopenia (Rare)
- Erythroblastopenia Anaphylactic reaction (Isolated cases)
- Oedema of Quincke (Isolated cases)
- Hypersensitivity (Rare)
- Injection site reaction (Common)
- Acute Porphyria (Rare)
- Rhinophyryngitis (Uncommon)
- Thrombophlebitis (Common)
- Sudden death
- Blood pressure (increase)
- Arteriovenous fistula thrombosis Myocardial infarction
- Aneurysm Hypertension (aggravation)
- Retinal vascular thrombosis Arterial thrombosis
- Myocardial Ischemia Hypertensive crisis Hypertension Deep thrombophlebitis Lung embolism
- Vomiting (Uncommon)
- Nausea (Very common)
- Diarrhoea (Very common)
- Muscle pain (Common)
- Bone pain (Common)
- Joint pain Convulsions (Uncommon)
- Stroke Headache Transient ischemic accident
- Hypertensive encephalopathy Stroke Brain haemorrhage Upper airway congestion (Uncommon)
- Cough (Common).